Core Viewpoint - The company announced the approval of a proposal to use part of its temporarily idle raised funds for cash management, amounting to a maximum of 650 million RMB, while ensuring that it does not affect the normal investment plans and operations [1] Group 1 - The company will hold its fourth board meeting and second supervisory board meeting on August 8, 2023 [1] - The board approved the use of up to 650 million RMB of convertible bonds for cash management [1] - The usage period for these funds is valid for 12 months from the date of board approval [1]

Core Viewpoint - 康泰医学 announced the approval of extending the authorization period for using temporarily idle raised funds for cash management [2] Group 1 - The fourth meeting of the company's fourth board of directors approved the proposal regarding the extension of the authorization [2]

Group 1 - The core viewpoint of the news is that 康泰医学 (Kangtai Medical) has shown a significant increase in its financial performance, with notable growth in revenue and net profit for the first quarter of 2025, despite a decline in stock price on the reporting date [1][3] - As of August 5, 2025, 康泰医学's stock closed at 19.51 yuan, down 5.01%, with a turnover rate of 10.9% and a trading volume of 276,200 hands, amounting to a transaction value of 549 million yuan [1] - The company reported total operating revenue of 112 million yuan for Q1 2025, representing a year-on-year increase of 12.77%, and a net profit attributable to shareholders of 16.44 million yuan, up 277.67% year-on-year [1] Group 2 - The company's non-recurring net profit reached 13.77 million yuan, reflecting a substantial year-on-year growth of 515.19% [1] - Financial ratios indicate a current ratio of 12.442, a quick ratio of 10.900, and a debt-to-asset ratio of 32.77%, suggesting strong liquidity and financial stability [1] - 康泰医学 has made investments in 6 companies, participated in 413 bidding projects, and holds 68 trademark registrations and 618 patents, along with 101 administrative licenses [2]

（文章来源：每日经济新闻） 康泰医学（SZ 300869，收盘价：19.51元）8月5日晚间发布公告称，公司第四届第二十一次董事会会议 于2025年8月5日在公司会议室召开。会议审议了《关于继续延长使用暂时闲置募集资金进行现金管理授 权期限的议案》等文件。 2024年1至12月份，康泰医学的营业收入构成为：医疗器械行业占比99.22%，其他业务占比0.78%。 ...

证券代码：300869 证券简称：康泰医学 公告编号：2025-056 债券代码：123151 债券简称：康医转债 康泰医学系统（秦皇岛）股份有限公司 第四届董事会第二十一次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 表决结果：同意 5 票；反对 0 票；弃权 0 票。本议案表决获得通过。 三、备查文件 1、第四届董事会第二十一次会议决议 特此公告 康泰医学系统（秦皇岛）股份有限公司董事会 康泰医学系统（秦皇岛）股份有限公司（以下简称"公司"）第四届董事会 第二十一次会议通知于 2025 年 7 月 25 日以电话方式向各位董事发出，会议于 2025 年 8 月 5 日以现场会议方式在公司会议室召开。会议由公司董事长胡坤先 生召集并主持，应出席会议的董事 5 人，实际出席会议的董事 5 人，公司高级管 理人员列席了会议。本次会议的召集、召开及表决，符合《中华人民共和国公司 法》和《康泰医学系统（秦皇岛）股份有限公司章程》（以下简称"《公司章程》"） 的规定，会议合法有效。 二、董事会会议审议情况 1.审议通过《关于继续 ...

证券代码：300869 证券简称：康泰医学 公告编号：2025-057 债券代码：123151 债券简称：康医转债 康泰医学系统（秦皇岛）股份有限公司 关于继续延长使用暂时闲置募集资金进行现金管理授权期限的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 康泰医学系统（秦皇岛）股份有限公司（以下简称"公司"或"康泰医学"） 于 2023 年 8 月 8 日召开了第四届董事会第三次会议、第四届监事会第二次会议，审 议通过了《关于使用部分暂时闲置募集资金进行现金管理的议案》，同意公司在确 保不影响募集资金投资计划正常进行和正常生产经营的情况下，使用不超过人民币 6.5 亿元的可转换公司债券暂时闲置募集资金进行现金管理，使用期限自董事会审议 通过之日起 12 个月内有效。公司于 2024 年 8 月 6 日召开了第四届董事会第十次会 议、第四届监事会第七次会议，审议通过了《关于延长使用暂时闲置募集资金进行 现金管理授权期限的议案》，同意在不影响募投项目投资建设和保证募集资金安全 使用的情况下，继续使用不超过人民币 6.5 亿元的可转换公司债券暂时闲置募集资金 进 ...

中信建投证券股份有限公司 为规范公司募集资金管理和使用，保护投资者权益，公司设立了募集资金专 项账户，对募集资金实行专户存储，并与子公司、保荐机构、存放募集资金的银 行签订了募集资金监管协议，募集资金到账后已全部存放于公司开设的募集资金 专项账户内。 二、募集资金投资项目情况 根据《康泰医学系统（秦皇岛）股份有限公司创业板向不特定对象发行可转 换公司债券募集说明书》披露的募集资金投资项目及募集资金使用计划，并经公 司第三届董事会第二十七次会议和第三届监事会第十五次会议分别审议通过的 1 《关于变更可转债募集资金用途的议案》，公司本次向不特定对象发行可转换公 司债券募集资金投资项目（以下简称"募投项目"）及募集资金使用计划如下： 三、使用部分闲置募集资金进行现金管理的情况 关于康泰医学系统（秦皇岛）股份有限公司继续延长使用暂时闲 置募集资金进行现金管理授权期限的核查意见 中信建投证券股份有限公司（以下简称"中信建投证券"或"保荐人"）作 为康泰医学系统（秦皇岛）股份有限公司（以下简称"康泰医学"或"公司"） 向不特定对象发行可转换公司债券的保荐人，根据《证券发行上市保荐业务管理 办法》《深圳证券交易所创业板股票 ...

Group 1 - Kangtai Medical (300869.SZ) shares fell by 4.19%, trading at 19.68 yuan, with a total transaction volume of 470 million yuan and a market capitalization of 7.9 billion yuan [2] - The company announced that major shareholder Wang Guili plans to reduce holdings by no more than 2.99% of the company's shares [2] - Other executives, including board members and senior management, plan to reduce their holdings by varying amounts, with the largest being 0.15% and the smallest being 0.03% [2] Group 2 - The reduction period for these share sales will be within three months after the announcement, starting fifteen trading days from the disclosure date [2]

Group 1 - China Shipbuilding plans to absorb and merge China Shipbuilding Industry Corporation through a share exchange, with trading suspension starting from August 13, 2025 [1] - China Shipbuilding was established in May 1998, focusing on shipbuilding (military and civilian), ship repair, marine engineering, and electromechanical equipment [1] Group 2 - SanChao New Materials intends to raise 250 million yuan through a private placement to Wuxi Boda He Yi Technology Co., with a share price of 20.04 yuan [2] - SanChao New Materials is undergoing a change in control, with Boda He Yi acquiring a total of 18.99 million shares, making it the controlling shareholder [2][3] Group 3 - Zhenyou Technology's actual controller plans to transfer 5% of the company's shares to Shenzhen Century Zhiyuan Private Equity Fund Management Co., at a price of 22.13 yuan per share, totaling 213 million yuan [4] - Zhenyou Technology was established in April 2005, focusing on the design, research, sales, and service of communication system equipment [4] Group 4 - Zhizheng Co. is set to undergo a major asset restructuring, with the Shanghai Stock Exchange scheduled to review the transaction on August 11, 2025 [5] - Zhizheng Co. was established in December 2004, specializing in high polymer materials for cables and semiconductor equipment [5] Group 5 - Shaoneng Co. reported a net profit of 95.90 million yuan for the first half of 2025, a year-on-year decrease of 42.43%, despite a revenue increase of 6.95% to 2.335 billion yuan [6] - Shaoneng Co. was established in June 1993, focusing on energy (electricity, heating, steam), ecological plant fiber products, and precision manufacturing [6] Group 6 - Lide New Energy reported a net profit of 8.95 million yuan for the first half of 2025, down 90.17%, with revenue of 496 million yuan, a decrease of 6.02% [7] - Lide New Energy was established in August 2013, focusing on investment, development, construction, and operation of wind and solar power projects [7] Group 7 - Zhongdian Environmental Protection achieved a net profit of 53.94 million yuan in the first half of 2025, a year-on-year increase of 2.87%, despite a revenue decline of 10.70% to 315 million yuan [8] - Zhongdian Environmental Protection was established in January 2001, specializing in the research, manufacturing, sales, and service of ecological environmental governance equipment [8] Group 8 - Qiaoyuan Co. has decided to terminate its intention to acquire the controlling stake in Deyang Hongchen Chemical Co. due to a lack of consensus among parties [10] - Qiaoyuan Co. was established in November 2001, focusing on the cleaning, collection, transportation, and treatment of municipal solid waste [10] Group 9 - ST Changfang plans to publicly transfer part of its assets, including the Ping Shan Changfang Industrial Park, with a starting price of 374 million yuan [12] - ST Changfang was established in May 2005, focusing on the research, design, production, and sales of LED off-grid lighting and other electronic products [12] Group 10 - He Xin Instruments reported a net loss of 17.46 million yuan for the first half of 2025, with revenue of 52.82 million yuan, down 48.88% [13] - He Xin Instruments was established in June 2004, focusing on the research, production, and sales of mass spectrometers and related technologies [13] Group 11 - Fengli Intelligent plans to raise no more than 730 million yuan through a private placement to specific investors, with funds allocated for various precision manufacturing projects [17] - Fengli Intelligent was established in April 1995, focusing on the research, production, and sales of small modulus gears and precision reducers [17] Group 12 - Tuo Jing Technology's employee stockholding platforms plan to transfer 6.99 million shares, accounting for 2.50% of the total share capital [21] - Tuo Jing Technology was established in April 2010, focusing on the research, production, and sales of high-end semiconductor thin film equipment [21] Group 13 - Tuo Jing Life plans to acquire 72.86% of Wuhan Kanglu Biological Technology Co. for 291 million yuan, with plans for further acquisitions in 2026 and 2027 [22] - Tuo Jing Life was established in November 2003, focusing on the research, production, and sales of in vitro diagnostic products [22]

据统计，8月4日，盘后包括达意隆、山外山、开普检测、吉宏股份、红旗连锁、通达股份、神火股份、 康泰医学、步科股份、飞鹿股份、能辉科技、晶雪节能、胜宏科技、赛腾股份、雪迪龙、中芯国际、工 大高科、成都先导、飞乐音响、华电辽能、三维股份、奥锐特在内的22家A股上市公司披露减持情况。 当日暂无A股上市公司披露增持情况。 | 1 | 达意障 | 董事兼高级管理人员吴小满计划减持不超过4.22万股股份 | | --- | --- | --- | | 2 | 山外山 | 大健康和力远健鲲合计减持2.26%公司股份 | | 3 | 开普检测 | 副总经理贺春、张冉拟减持不超过0.54%公司股份 | | 4 | 吉宏股份 | 毒事长干亚朋计划减持不超过304万股 | | 5 | 红旗连锁 | 永辉超市拟减持不超过1%股份 | | 6 | 通达股份 | 控股股东拟减持不超过3%公司股份 | | 1 | 神火股份 | 普天工贸拟减持0.90%公司股份 | | 8 | 康泰医学 | 持股5%以上股东及部分董事、高管拟减持不超过3.59%股份 | | 9 | 步科股份 | 控股股东上海步进计划减持不超过3%公司股份 | | 10 | ...